These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 7514026)

  • 21. p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumour tissue.
    Wild CP; Ridanpää M; Anttila S; Lubin R; Soussi T; Husgafvel-Pursiainen K; Vainio H
    Int J Cancer; 1995 Jun; 64(3):176-81. PubMed ID: 7622306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Serum levels of CEA and ferritin in lung cancer before, during and after radiotherapy].
    Tatsuno I; Konishi K
    Rinsho Hoshasen; 1983 Nov; 28(12):1487-90. PubMed ID: 6323796
    [No Abstract]   [Full Text] [Related]  

  • 23. Complementary reactivities of anti-carcinoembryonic antigen and antitumor-associated glycoprotein 72 monoclonal antibodies in lung carcinomas.
    Battista P; Muraro R; Mammarella S; Curia MC; Colasante A; Rosini S; Lesti G; Sacco R; French D; Frati L
    Cancer Res; 1990 Nov; 50(21):6987-94. PubMed ID: 1698547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human monoclonal antibody 28K29 highly reactive with lung adenocarcinomas of all grades of differentiation and with large cell carcinomas.
    Yoshinari K; Aoki T; Yamada H; Sugawara I
    Lung Cancer; 1999 Aug; 25(2):95-103. PubMed ID: 10470843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autoimmunity to the M(r) 32,000 subunit of replication protein A in breast cancer.
    Tomkiel JE; Alansari H; Tang N; Virgin JB; Yang X; VandeVord P; Karvonen RL; Granda JL; Kraut MJ; Ensley JF; Fernández-Madrid F
    Clin Cancer Res; 2002 Mar; 8(3):752-8. PubMed ID: 11895905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Head and neck cancer and p53-immunogenicity.
    Maass JD; Gottschlich S; Goeroegh T; Lippert BM; Werner JA
    Anticancer Res; 1997; 17(4B):2873-4. PubMed ID: 9329551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
    Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
    Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum p53 antibodies: predictors of survival in small-cell lung cancer?
    Murray PV; Soussi T; O'Brien ME; Smith IE; Brossault S; Norton A; Ashley S; Tavassoli M
    Br J Cancer; 2000 Dec; 83(11):1418-24. PubMed ID: 11076647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The presence of anti-p53 antibodies in sera prior to thoracic surgery in non small cell lung cancer patients: its implications on tumor volume, nodal involvement, and survival.
    Bergqvist M; Brattström D; Lamberg K; Hesselius P; Wernlund J; Larsson A; Wagenius G
    Neoplasia; 2003; 5(4):283-7. PubMed ID: 14511399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer.
    Rosenfeld MR; Malats N; Schramm L; Graus F; Cardenal F; Viñolas N; Rosell R; Torà M; Real FX; Posner JB; Dalmau J
    J Natl Cancer Inst; 1997 Mar; 89(5):381-5. PubMed ID: 9060960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer.
    Trivers GE; De Benedetti VM; Cawley HL; Caron G; Harrington AM; Bennett WP; Jett JR; Colby TV; Tazelaar H; Pairolero P; Miller RD; Harris CC
    Clin Cancer Res; 1996 Oct; 2(10):1767-75. PubMed ID: 9816128
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ADAM28 is a serological and histochemical marker for non-small-cell lung cancers.
    Kuroda H; Mochizuki S; Shimoda M; Chijiiwa M; Kamiya K; Izumi Y; Watanabe M; Horinouchi H; Kawamura M; Kobayashi K; Okada Y
    Int J Cancer; 2010 Oct; 127(8):1844-56. PubMed ID: 20112342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fucosylated type-2 chain polylactosamine antigens in human lung cancer.
    Zenita K; Kirihata Y; Kitahara A; Shigeta K; Higuchi K; Hirashima K; Murachi T; Miyake M; Takeda T; Kannagi R
    Int J Cancer; 1988 Mar; 41(3):344-9. PubMed ID: 2831158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The presence of anti-p53 antibodies in sera from patients with oesophageal carcinoma: correlation to treatment, tumour volume and survival.
    Bergström S; Dreilich M; Wagenius G; Brattström D; Larsson A; Hesselius P; Bergqvist M
    In Vivo; 2004; 18(5):615-20. PubMed ID: 15523902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Divergence between the high rate of p53 mutations in skin carcinomas and the low prevalence of anti-p53 antibodies.
    Moch C; Moysan A; Lubin R; de la Salmonière P; Soufir N; Galisson F; Vilmer C; Venutolo E; Le Pelletier F; Janin A; Basset-Séguin N
    Br J Cancer; 2001 Dec; 85(12):1883-6. PubMed ID: 11747330
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Usefulness of serum carboxy-terminal telopeptide of type I collagen (ICTP) as a marker of bone metastasis from lung cancer.
    Horiguchi T; Tachikawa S; Kondo R; Hirose M; Teruya S; Ishibashi A; Banno K
    Jpn J Clin Oncol; 2000 Apr; 30(4):174-9. PubMed ID: 10830985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum anti-p53 antibody detection in carcinomas and the predictive values of serum p53 antibodies, carcino-embryonic antigen and carbohydrate antigen 12-5 in the neoadjuvant chemotherapy treatment for III stage non-small cell lung cancer patients.
    Yu DH; Li JH; Wang YC; Xu JG; Pan PT; Wang L
    Clin Chim Acta; 2011 May; 412(11-12):930-5. PubMed ID: 21277290
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel monoclonal antibody-defined antigen which distinguishes human non-small cell from small cell lung carcinomas.
    Sobol RE; Peters RE; Astarita RW; Hofeditz C; Masui H; Burton D; Handley HH; Glassy MC; Fairshter R; Carlo DJ
    Cancer Res; 1986 Sep; 46(9):4746-50. PubMed ID: 3015395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Expression and clinical significance of p53 protein and p21(WAF1) in non-small-cell lung carcinoma].
    Zhang H; Lü F; Yue W; Yan H; Deng L; Wang S
    Zhonghua Bing Li Xue Za Zhi; 2000 Oct; 29(5):328-30. PubMed ID: 11866928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.